REQUEST A DEMO
Total
USD $0.00
Search more companies

Novo Nordisk Pharma UAB (Lithuania)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers
Full name: Novo Nordisk Pharma UAB Profile Updated: November 01, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Russian Download a sample report

Novo Nordisk Pharma UAB is an enterprise in Lithuania, with the main office in Vilnius. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. The company was established on May 12, 2005. It currently has a total number of 23 (2024) employees. From the latest financial highlights, Novo Nordisk Pharma UAB reported a net sales revenue increase of 33.17% in 2023. In, 2023, the company’s net profit margin increased by 0.22%.

Headquarters
J. Jasinskio g. 16B
Vilnius; Vilnius county; Postal Code: LT-03163

Contact Details: Purchase the Novo Nordisk Pharma UAB report to view the information.

Website: http://www.novonordisk.lt

Basic Information
Total Employees:
Purchase the Novo Nordisk Pharma UAB report to view the information.
Outstanding Shares:
Purchase the Novo Nordisk Pharma UAB report to view the information.
Registered Capital:
Purchase the Novo Nordisk Pharma UAB report to view the information.
Incorporation Date:
May 12, 2005
Key Executives
Purchase this report to view the information.
General Director
Company Performance
Financial values in the chart are available after Novo Nordisk Pharma UAB report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
33.17%
Total operating revenue
33.17%
Net Profit (Loss) for the Period
42.37%
Total equity
69.5%
Net Profit Margin
0.22%
Return on Equity (ROE)
-7.81%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?